Get the Stockscreener App
0.8405
1.23%
-0.0105
After Hours:
.84
-0.0005
-0.06%
Renovorx Inc stock is traded at $0.8405, with a volume of 814.69K.
It is down -1.23% in the last 24 hours and down -11.61% over the past month.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
See More
Previous Close:
$0.851
Open:
$0.9003
24h Volume:
814.69K
Relative Volume:
3.32
Market Cap:
$30.80M
Revenue:
-
Net Income/Loss:
$-9.16M
P/E Ratio:
-1.4746
EPS:
-0.57
Net Cash Flow:
$-8.75M
1W Performance:
-2.83%
1M Performance:
-11.61%
6M Performance:
-32.22%
1Y Performance:
-11.54%
1-Day Range:
$0.81
$0.93
1-Week Range:
$0.81
$0.9385
52-Week Range:
$0.7006
$1.45
Renovorx Inc Stock (RNXT) Company Profile
Name
Renovorx Inc
Sector
Industry
Phone
408-800-2649
Address
2570 W. EL CAMINO REAL, STE. 320,, MOUNTAIN VIEW
Compare RNXT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RNXT
Renovorx Inc
|
0.8405 | 31.19M | 0 | -9.16M | -8.75M | -0.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Renovorx Inc Stock (RNXT) Latest News
Guidance Update: Is RenovoRx Inc stock overvalued or fairly pricedJuly 2025 Recap & AI Driven Price Predictions - baoquankhu1.vn
US Market Recap: Whats the outlook for RenovoRx Incs sectorM&A Rumor & AI Enhanced Trading Alerts - baoquankhu1.vn
RenovoRx advances RenovoCath adoption at U.S. cancer centers - Yahoo Finance
RNXT Should I Buy - Intellectia AI
RenovoRx Advancing RenovoCath® Adoption at U.S. Cancer Centers, Strengthening Clinical and Commercial Momentum - Investing News Network
After 700 cancer procedures, RenovoCath gets new doctor-led commercial push - Stock Titan
Targeted chemo delivery for pancreatic cancer to feature at 2026 SIR meeting - Stock Titan
RNXT PE Ratio & Valuation, Is RNXT Overvalued - Intellectia AI
RenovoRx (RNXT) Price Target Increased by 10.66% to 6.88 - Nasdaq
Hedge Fund Bets: Will eBay Inc Preferred Security stock hit new highs in YEAR2025 Bull vs Bear & Long-Term Capital Growth Strategies - baoquankhu1.vn
Is RenovoRx Inc. stock overvalued or fairly pricedSwing Trade & Daily Technical Forecast Reports - mfd.ru
Dow Update: How much upside does RenovoRx Inc haveJuly 2025 Market Mood & Weekly Top Stock Performers List - baoquankhu1.vn
RenovoRx (NASDAQ:RNXT) vs. MetaVia (NASDAQ:MTVA) Head-To-Head Survey - Defense World
Mark Voll Joins RenovoRx as Chief Financial Officer - Medical Product Outsourcing
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
RenovoRx (NASDAQ:RNXT) Price Target Raised to $13.00 at Ascendiant Capital Markets - Defense World
RenovoRx (RNXT): Analyst Raises Price Target Following Positive Outlook | RNXT Stock News - GuruFocus
Micron To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Tuesday - Sahm
Why RenovoRx Inc. stock remains resilientTrade Performance Summary & Safe Entry Point Alerts - mfd.ru
Is RenovoRx Inc. a top pick in the sector2025 Biggest Moves & Growth Focused Entry Point Reports - mfd.ru
Can RenovoRx Inc. deliver consistent EPS growthJuly 2025 Trends & Expert Approved Trade Ideas - mfd.ru
RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results - MSN
Bank Watch: Can RenovoRx Inc deliver consistent EPS growth2025 Market Outlook & Fast Moving Stock Trade Plans - baoquankhu1.vn
Aug Catalysts: What drives XYZGs stock price2025 EndofYear Setup & AI Powered Buy/Sell Recommendations - baoquankhu1.vn
What’s the beta of RenovoRx Inc. stockJuly 2025 Snapshot & Accurate Buy Signal Notifications - mfd.ru
RenovoRx formation of RenovoCath Medical Advisory Board to support clinical and strategic initiatives - marketscreener.com
RenovoRx Forms Medical Advisory Board to Support RenovoCath - Intellectia AI
RenovoRx Establishes RenovoCath® Medical Advisory Board - Investing News Network
Renovorx Formation Of Renovocath Medical Advisory Board To Support Clinical And Strategic Initiatives - TradingView
RenovoRx, Inc. Establishes Medical Advisory Board to Advance RenovoCath Clinical Initiatives and Targeted Oncology Therapies - Quiver Quantitative
RenovoRx, Inc. Establishes RenovoCath Medical Advisory Board - marketscreener.com
Top radiologists join new board to shape targeted cancer drug delivery - Stock Titan
RNXT SEC FilingsRenovorx Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Aug Ideas: Is RenovoRx Inc stock overvalued or fairly pricedWeekly Investment Recap & Safe Swing Trade Setup Alerts - baoquankhu1.vn
RenovoRx, Inc. Announces Change of Principal Accounting Officer - marketscreener.com
RenovoRx Appoints Veteran Executive Mark Voll as CFO - TipRanks
RenovoRx Appoints Experienced Public Company Executive Mark Voll as Chief Financial Officer - Investing News Network
Renovorx, Inc. Appoints Mark Voll as Chief Financial Officer, Effective from February 1, 2026 - marketscreener.com
RenovoRx announces new clinical data on TAMP therapy platform - TipRanks
RenovoRx to Present New Clinical Data on Optimizing Drug Delivery in Solid Tumors at 2026 Society of Interventional Oncology Annual Meeting - Quiver Quantitative
How real-time pressure readings could sharpen chemo targeting - Stock Titan
RenovoRx Announces Clinical Data Supporting the TAMP™ Therapy Platform will be Presented at the SIO 2026 Annual Scientific Meeting - The Manila Times
Exit Recap: Is SunCar Technology Group Inc Equity Warrant forming a breakout patternJuly 2025 Market Mood & Community Trade Idea Sharing Platform - baoquankhu1.vn
RenovoRx (NASDAQ:RNXT) Upgraded at Jones Trading - Defense World
Pharma News: How does RenovoRx Inc perform in inflationary periods2025 Volume Leaders & Weekly Momentum Stock Picks - baoquankhu1.vn
Jones Trading initiates coverage on RenovoRx stock with Buy rating By Investing.com - Investing.com South Africa
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors - The Globe and Mail
Jones Trading initiates coverage on RenovoRx stock with Buy rating - Investing.com
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 Society of Interventional Oncology Annual Scientific Meeting - BioSpace
RenovoRx Announces Acceptance of Clinical Data Abstract at 2026 S - The National Law Review
RenovoRx, Inc. (NASDAQ:RNXT) Is Expected To Breakeven In The Near Future - simplywall.st
Renovorx Inc Stock (RNXT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Renovorx Inc Stock (RNXT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Agah Ramtin | Chief Medical Officer |
Dec 31 '25 |
Buy |
0.86 |
9,795 |
8,424 |
788,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 30 '25 |
Buy |
0.83 |
205 |
169 |
778,665 |
| Bagai Shaun | Chief Executive Officer |
Dec 18 '25 |
Buy |
0.90 |
5,000 |
4,506 |
340,040 |
| Bagai Shaun | Chief Executive Officer |
Dec 17 '25 |
Buy |
0.85 |
5,000 |
4,262 |
335,040 |
| Agah Ramtin | Chief Medical Officer |
Dec 16 '25 |
Buy |
0.85 |
12,000 |
10,200 |
778,460 |
| Agah Ramtin | Chief Medical Officer |
Dec 05 '25 |
Buy |
0.96 |
10,000 |
9,600 |
766,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 24 '25 |
Buy |
0.80 |
12,000 |
9,600 |
756,460 |
| Agah Ramtin | Chief Medical Officer |
Nov 21 '25 |
Buy |
0.80 |
10,000 |
8,000 |
744,460 |
| Bagai Shaun | Chief Executive Officer |
Aug 22 '25 |
Buy |
0.95 |
5,000 |
4,748 |
325,040 |
| Bagai Shaun | Chief Executive Officer |
Aug 25 '25 |
Buy |
0.91 |
5,000 |
4,549 |
330,040 |
3.69%
0.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):